IMMUNABS
3.8.2022 16:02:08 CEST | Business Wire | Press release
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 10:00:00 CEST | Press release
Including Executives and Policymakers from the UK Government, NVIDIA, AWS, Tony Blair Institute, AstraZeneca and Virgin Atlantic The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead
MOVIVA® launch spotlight at ESGE Days 20267.5.2026 09:58:00 CEST | Press release
“Turn down the food noise” During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.”
Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 09:57:00 CEST | Press release
GBCI Europe Impact Report 2026 highlights that 53% of European real estate leaders prioritize resilience as a financial imperative. Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of t
Criteo Selects Navan to Modernize Global Travel Management7.5.2026 09:00:00 CEST | Press release
Global commerce intelligence platform delivers high employee satisfaction with Navan Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Gli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom